This signalling pathway can be activated directly by deregulated RAS oncogenes (mutated in about 25% of melanomas), or indirectly, for example as a result of PTEN loss (the latter commonly found in BRAF-mutated melanomas, which constitute 50-60% of the cutaneous forms of this disease) [42]. This evidence concerns the gene PTEN and melanoma.